ADMA Biologics (ADMA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
139.6mn → 244.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
▲174% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
$31.9M returned vs $27.8M of FCF in FY25. The gap comes off the balance sheet (see net cash).
29¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Over this window: gross 1.4% → 57.4%. Net margin 28.8% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 519.2 | 510.2 | 426.5 | 258.2 | 154.1 | 80.9 | ▲19.6% | +58.4% |
Cost of revenue | 163.4 | 217.4 | 206.9 | 169.3 | 118.8 | 79.8 | ▲5.1% | +28.5% |
Gross profit | 355.8 | 292.8 | 219.6 | 88.9 | 35.3 | 1.2 | ▲33.3% | +297.5% |
Research & development | 14.5 | 4.8 | 1.8 | 3.3 | 3.6 | 3.6 | ▲162.7% | +6.9% |
Selling, general & admin | 107.8 | 96.4 | 78.4 | 63.3 | 70.3 | 55.2 | ▲23.0% | +15.0% |
Total operating expenses | 122.5 | 101.3 | 80.6 | 67.3 | 74.6 | 59.5 | ▲25.8% | +14.2% |
Operating incomefeeds ROC rank | 241.2 | 191.4 | 139.0 | 21.6 | −39.4 | −58.4 | ▲37.7% | — |
Other income, net | −6.7 | −8.8 | −13.3 | −49.9 | −26.5 | −13.3 | — | — |
Pretax income | 234.6 | 182.7 | 125.7 | −28.2 | −65.9 | −71.6 | ▲45.3% | — |
Income tax | 52.1 | 35.7 | −72.0 | 0.0 | 0.0 | — | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 182.4 | 146.9 | 197.7 | −28.2 | −65.9 | −71.6 | ▼25.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.77 | 0.60 | 0.81 | −0.13 | −0.33 | −0.51 | ▼25.9% | — |
Diluted shares (mn) | 225.82 | 244.90 | 243.34 | 223.98 | 197.87 | 139.58 | ▲0.6% | +15.1% |
| Margins | ||||||||
Gross margin53rd pct in Healthcare | 68.5% | 57.4% | 51.5% | 34.4% | 22.9% | 1.4% | ▲5.9pp | +55.9pp |
Operating margin | 46.5% | 37.5% | 32.6% | 8.4% | −25.5% | −72.1% | ▲4.9pp | +109.6pp |
Net margin96th pct in Healthcare | 35.1% | 28.8% | 46.4% | −10.9% | −42.8% | −88.5% | ▼17.6pp | +117.3pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was ADMA Biologics' revenue last fiscal year?
ADMA Biologics reported revenue of $510.2M in fiscal 2025, up 19.6% from fiscal 2024.
What was ADMA Biologics' net income?
ADMA Biologics reported net income of $146.9M in fiscal 2025, a net margin of 28.8%.

